The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Suramin binds to platelet‐derived growth factor and inhibits its biological activity
Abstract
The polyanion suramin was recently found to inhibit binding of 125 I‐PDGF (platelet‐derived growth factor) to Balb/e 3T3 cell membranes. Cultured Swiss 3T3 cells were used to investigate the mode of action of suramin and to monitor its effect on the biological activity of PDGF. Evidence is presented that suramin inhibits cellular binding of PDGF by binding to PDGF itself, thereby preventing it from binding to its cell surface receptor: First, while suramin inhibited I‐PDGF binding with a hail maximum inhibition concentration of ∼60 μM or 90 μg/ml in a simultaneous competition assay, it was inactive in a sequential radioreciptor assay, in which an inhibitor is expected to be active if it interacts with the receptor (even with relatively low affinity) but to be inactive if it interacts with PDGF. Second, suramin prevented immunoprecipitation of 125 I‐PDGF in a dose‐dependent manner, with a half maximum effective concentration of ∼50 μM. Furthermore, suramin efficiently dissociated 125 I‐PDGF bound to its cell surface receptor, whereas unlabeled PDGF even in large excess was virtually inactive. This is also in line with the proposed direct interaction between PDGF and suramin, since such an interaction can he envisaged to induce a conformational change in the PDGF‐receptor complex, resulting in an increased off‐rate of the complex. Reduced 125 I‐PDGF binding in the presence of suramin correlated directly with a suramin dose‐dependent inhibition of PDGF‐induced incorporation of 3 H‐thymidine into quiescent Swiss 3T3 cells and of the proliferation of these cells. These observations suggest that suramin, by complexing with PDGF, renders this mitogen unable to bind to its physiological receptor and, thereby, prevents PDGF‐initiated biological activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Atherosclerosis: (First of Two Parts)
Ross, R., & Glomset, J. A. (1976) · New England Journal of Medicine · doi:10.1056/nejm197608122950707 · Cited by 2,014
Ross, R., Glomset, J., Kariya, B., & Harker, L. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1207 · Cited by 1,847
Ross, R., & Glomset, J. A. (1973) · Science · doi:10.1126/science.180.4093.1332 · Cited by 1,501
Platelets as a source of fibroblast growth-promoting activity
Kohler, N., & Lipton, A. (1974) · Experimental Cell Research · doi:10.1016/0014-4827(74)90484-4 · Cited by 626
Platelet-derived growth factor. I. High yield purification and evidence for multiple forms.
Raines, E. W., & Ross, R. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34649-0 · Cited by 449
Heldin, C. H., Westermark, B., & Wasteson, A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3664 · Cited by 420
Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-III
Mitsuya, H., Popovic, M., Yarchoan, R., Matsushita, S., Gallo, R. C., & Broder, S. (1984) · Science · doi:10.1126/science.6091268 · Cited by 397
Platelet-derived growth factor. II. Specific binding to cultured cells.
Bowen-Pope, D. F., & Ross, R. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34650-7 · Cited by 361
Cooper, J. A., Bowen-Pope, D. F., Raines, E., Ross, R., & Hunter, T. (1982) · Cell · doi:10.1016/0092-8674(82)90426-3 · Cited by 361
Nishimura, J., Huang, J. S., & Deuel, T. F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4303 · Cited by 289
Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses
De Clercq, E. (1979) · Cancer Letters · doi:10.1016/0304-3835(79)90017-x · Cited by 288
Suramin: With Special Reference to Onchocerciasis
Hawking, F. (1978) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60486-x · Cited by 284
Vogel, A., Raines, E., Kariya, B., Rivest, M. J., & Ross, R. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.6.2810 · Cited by 252
Ek, B., & Heldin, C. H. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34044-4 · Cited by 248
Williams, L. T., Tremble, P. M., Lavin, M. F., & Sunday, M. E. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42987-5 · Cited by 202
Specific covalent binding of platelet-derived growth factor to human plasma alpha 2-macroglobulin.
Huang, J. S., Huang, S. S., & Deuel, T. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.2.342 · Cited by 187
Garrett, J. S., Coughlin, S. R., Niman, H. L., Tremble, P., Giels, G. M., & Williams, L. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.23.7466 · Cited by 155
Heldin, C., Wasteson, Å., & Westermark, B. (1977) · Experimental Cell Research · doi:10.1016/0014-4827(77)90023-4 · Cited by 134
Raines, E. W., Bowen‐Pope, D. F., & Ross, R. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3424 · Cited by 97
Duke, B. O. L. (1968) · PubMed · Cited by 28
Cited by
The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Meisenhelder, J., Suh, P.-G., Rhee, S. G., & Hunter, T. (1989) · Cell · doi:10.1016/0092-8674(89)90048-2 · Cited by 955
Fibrogenic cytokines: the role of immune mediators in the development of scar tissue
Kovacs, E. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90107-5 · Cited by 590
Tuder, R. M., Flook, B. E., & Voelkel, N. F. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117858 · Cited by 588
Kumar, R. K. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.5.1234 · Cited by 559
Metadata
- Authors
- Hosang, M.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 1985-01
- Volume
- 29
- Issue
- 3
- Pages
- 265-273
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1972580962
- Cited by
- 254
- References
- 20
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.